Ustekinumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ustekinumab: From Plaque Psoriasis to Dermatitis
One-Sentence Summary
Ustekinumab (an IL-12/IL-23 p40 antagonist) was originally developed for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The TxGNN model predicts it may also be effective for Dermatitis (particularly atopic dermatitis), with 7 clinical trials and 20 publications currently supporting this direction, including two completed Phase 2 RCTs testing this exact indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis (per literature evidence, PMID 36208443) |
| Predicted New Indication | Dermatitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The DrugBank record for ustekinumab does not provide a structured original_moa field, but the literature evidence gathered in this pack consistently describes its mechanism: ustekinumab is a fully human IgG1 monoclonal antibody that binds the shared p40 subunit of IL-12 and IL-23, thereby suppressing Th1, Th17, and Th22 activation (PMID 27304428). This IL-12/23 blockade is the same mechanism that underlies its approved efficacy in plaque psoriasis, an inflammatory Th17-driven skin disease.
Atopic dermatitis — the dermatitis subtype most represented in the evidence below — also involves Th17/Th22 activation alongside the classic Th2 axis, giving a plausible mechanistic bridge from psoriasis to dermatitis. Both are chronic, immune-mediated inflammatory skin diseases, and clinical investigators have directly tested this hypothesis: two completed Phase 2 RCTs (in Japanese and Western populations) evaluated ustekinumab specifically in moderate-to-severe/severe atopic dermatitis, along with a mechanistic study showing down-regulation of Th2/Th22 gene expression after treatment (PMID 27745907). This combination of shared pathway biology and existing dedicated trials makes the TxGNN prediction mechanistically reasonable rather than purely statistical.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01945086 | Phase 2 | Completed | 79 | Randomized, double-blind, placebo-controlled trial of ustekinumab in adult Japanese patients with severe atopic dermatitis |
| NCT01806662 | Phase 2 | Completed | 32 | Randomized pilot study of ustekinumab in chronic atopic dermatitis patients with sub-optimal response to prior therapy |
| NCT02074982 | Phase 3 | Completed | 676 | Head-to-head RCT of secukinumab vs. ustekinumab (PASI-based efficacy) in moderate-to-severe plaque psoriasis |
| NCT05535738 | Phase 2/3 | Recruiting | 45 | Suction-blister contact dermatitis model studying how biologic therapies (incl. anti-IL12/23) modulate skin inflammation |
| NCT01356758 | N/A | Completed | 126 | Cardiovascular risk assessment in severe psoriasis patients treated with biologic agents including ustekinumab |
| NCT07041112 | N/A | Completed | 1000 | Retrospective cohort evaluating 10-year drug survival of biologics (including ustekinumab) in cutaneous psoriasis/psoriatic arthritis |
| NCT07352566 | Phase 4 | Not yet recruiting | 10 | Microdevice platform testing multiple FDA-approved atopic dermatitis/psoriasis drugs directly in skin |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28338223 | 2017 | RCT (Phase 2) | Br J Dermatol | Randomized, double-blind, placebo-controlled Phase 2 study showing ustekinumab efficacy/safety in Japanese patients with severe atopic dermatitis |
| 27304428 | 2017 | RCT (Phase 2) | Exp Dermatol | Ustekinumab (IL-12/IL-23p40 antagonist) evaluated for efficacy and safety in adults with moderate-to-severe atopic dermatitis |
| 33849369 | 2022 | Observational (real-world) | J Dermatolog Treat | Real-world evidence analysis on effectiveness of ustekinumab in atopic dermatitis patients |
| 27745907 | 2017 | Clinical study | J Am Acad Dermatol | Ustekinumab treatment in severe atopic dermatitis shown to down-regulate Th2/Th22 gene expression |
| 29164954 | 2018 | Systematic Review | J Dermatolog Treat | Systematic review of ustekinumab efficacy and safety in the treatment of atopic dermatitis |
| 33074565 | 2021 | Systematic Review/Meta-analysis | Allergy | EAACI evidence review of systemic treatments (including biologics) for moderate-to-severe atopic dermatitis |
| 29098604 | 2018 | Systematic Review/Meta-analysis | Am J Clin Dermatol | Meta-analysis assessing whether biologics, including ustekinumab, are efficacious in atopic dermatitis |
| 36208443 | 2022 | Review | Dermatol Ther | Review of off-label uses of ustekinumab beyond its approved psoriasis/Crohn's/UC indications |
| 39987634 | 2025 | Observational (FAERS analysis) | Int Immunopharmacol | Real-world adverse-event analysis of ustekinumab safety in psoriasis and psoriatic arthritis |
| 37929636 | 2024 | Case Report | Australas J Dermatol | Case of dual biologic therapy (ustekinumab + dupilumab) in a patient with severe atopic dermatitis and Crohn's disease, no drug interaction observed over 7 months |
Norway Market Information
Ustekinumab is currently not marketed in Norway under this evidence pack, and no authorization records (product licenses, dosage forms) are available in the dataset.
Safety Considerations
Please refer to the package insert for safety information.
(Note: Key warnings, contraindications, and drug-drug interaction data are flagged in the evidence pack as a Blocking data gap — TFDA-equivalent label information has not yet been retrieved and is required before this candidate can proceed to a formal safety evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale and existing evidence base (7 trials, 20 publications, including two completed Phase 2 RCTs directly testing ustekinumab in atopic dermatitis) are encouraging, but a Blocking data gap on official label warnings/contraindications prevents entry into the safety evaluation stage, and the drug is not currently marketed in Norway.
To proceed, the following is needed:
- Official package insert / label data (warnings, contraindications) to resolve the Blocking data gap and enable a formal S1 safety review
- Confirmation of detailed mechanism-of-action documentation via DrugBank (to resolve the MOA data gap)
- Assessment of regulatory pathway for market entry in Norway, since no authorizations currently exist
- Additional Phase 3-level trial data specific to the dermatitis indication, as current direct evidence is limited to completed Phase 2 studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.